



Elliot's B® (sodium chloride, sodium bicarbonate, anhydrous dextrose, magnesium sulfate, potassium chloride, calcium chloride and sodium phosphate)

Last Review Date: August 1, 2019

Number: MG.MM.PH.xxx

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated, GHI HMO Select, ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Elliot's B® Solution is a sterile, nonpyrogenic, isotonic solution containing no bacteriostatic preservatives.

Elliot's B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.

Elliot's B Solution provides a buffered salt solution for use as a diluent for the intrathecal administration of methotrexate sodium and cytarabine. It has been demonstrated that Elliot's B Solution is comparable to cerebrospinal fluid in pH, electrolyte composition, glucose content, and osmolarity.

Length of Authorization

Coverage will be provided for 2 months and may be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- Per package insert

I. INITIAL APPROVAL CRITERIA

Elliot's B may be considered medically necessary if one of the below conditions are met **AND** use is consistent with the medical necessity criteria that follows:

1. meningeal leukemia or lymphocytic lymphoma

- a. Patient must have a diagnosis of meningeal leukemia or lymphocytic lymphoma

Elliot's B® (sodium chloride, sodium bicarbonate, anhydrous dextrose, magnesium sulfate, potassium chloride, calcium chloride and sodium phosphate)

Last review: August 1, 2019

Page 2 of 2

- b. Elliotts B solution will be used for intrathecal administration only, following an appropriate dosing regimen per product labeling for methotrexate sodium and cytarabine

Limitations/Exclusions

N/A

II. RENEWAL CRITERIA

- Patient continues to meet INITIAL APPROVAL CRITERIA.
- Member is responding positively to therapy.

Dosage/Administration

| Indication | Dose |
|--|---|
| diluent for the intrathecal administration of methotrexate sodium and cytarabine | – See product labeling for methotrexate sodium and cytarabine |

Applicable Procedure Codes

| | |
|-------|---------------------------------------|
| J9175 | Injection, Elliotts' B solution, 1 mL |
|-------|---------------------------------------|

Applicable NDCs

| | |
|---------------|--|
| 55792-0007-10 | 10 mL ampule in 1 Box; sterile buffered intrathecal electrolyte/dextrose injection |
| 55792-0007-01 | 10 mL in 1 Ampule; |

Applicable Diagnosis Codes

| ICD-10 | ICD-10 Description |
|--------|---------------------------------------|
| C81.3 | Lymphocyte depleted Hodgkin lymphoma |
| C70.1 | Malignant neoplasm of spinal meninges |

References

- 1) Product Information: Elliotts B solution. Lukare Medical, LLC; Scotch Plains, NJ 07076.
- 2) Cradock JC, et al. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. American Journal of Hospital Pharmacy (1978); 35:402.
- 3) Clinical Pharmacology Elsevier Gold Standard. 2019.
- 4) Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2019.